Stem cell study seeks to wean non-related transplant recipients from anti-rejection drugs

May 28, 2009

The immunosuppressive drugs required by organ transplant recipients after surgery can have serious side effects with prolonged use, including infection, heart disease and cancer. In an effort to reduce, or potentially eliminate the need for anti-rejection medications, researchers at Northwestern Memorial Hospital and Northwestern University's Feinberg School of Medicine are investigating the efficacy of a stem cell transplant after organ transplant. The study, which is the first to test the protocol on non-related living donor kidney pairs, involves transplanting stem cells from the kidney donor into the recipient one day following the organ transplant surgery.

"What's unique about this study is that the donor and recipient do not have to be related and do not have to be immunologically identical. If successful, the procedure will open the door for many people who could potentially benefit from the stem cell protocol and avoid life-long use of anti-rejection drugs post ," commented Joseph Leventhal, MD, PhD, transplant surgeon, director of the living donor program and associate professor of surgery at Northwestern University's Feinberg School of Medicine.

Stem cells are formed at the marrow and are common blood cells from which other specialized , like immune cells, develop. By transplanting stem cells from the kidney donor into the recipient, researchers hope to prove that the cells will mature in the recipient's body and work to prevent rejection of the new organ, thus allowing the immune system to accept the organ as its own.

Similar studies involving stem cell transplants for organ recipients have included donors and recipients who are siblings and are immunologically identical, something that only occurs in about 25 percent of sibling pairs. "Since approximately one-third of living donor kidney transplant pairs are non-related, existing studies only target a small group of patients. Our goal is to identify a protocol that will expand the pool of patients who qualify for stem cell transplant post and help patients achieve a better quality of life post organ transplant," commented Michael Abecassis, MD, chief of the division of organ transplantation and dean of clinical affairs for Northwestern University's Feinberg School of Medicine.

The process begins about one month before the kidney transplant, when stem cells are collected from the kidney donor using a process called apheresis. The recipient also undergoes apheresis to collect stem cells and undergoes a single dose of radiation one day prior to surgery to suppress the bone marrow so the donor's stem cells have more space to grow in the recipient's body. The kidney transplant then occurs in the standard manner and one day following the transplant surgery, the donor are infused into the transplant recipient.

"In a standard kidney transplant, the donor agrees to donate their kidney. In this situation, the individual is asked to donate part of their immune system as well, which we hope will build tolerance in the recipient's body," adds Dr. Leventhal.

Following surgery, the patient is monitored for rejection of the kidney and over time, is weaned off of anti-rejection medications.

The first subjects to participate in the research study underwent surgery on Thursday, February 26th. A total of 30 subjects will be enrolled in the Phase I trial to test the safety of the procedure. In order to qualify, the donor and recipient pairs must be blood-type compatible and have a negative cross-match, which means that testing has been done to confirm the recipient does not have antibodies in the blood that would cause rejection of the kidney.

Source: Northwestern Memorial Hospital (news : web)

Explore further: Novel marker discovered for stem cells derived from human umbilical cord blood

add to favorites email to friend print save as pdf

Related Stories

Recommended for you

New pain relief targets discovered

5 hours ago

Scientists have identified new pain relief targets that could be used to provide relief from chemotherapy-induced pain. BBSRC-funded researchers at King's College London made the discovery when researching ...

Building 'smart' cell-based therapies

6 hours ago

A Northwestern University synthetic biology team has created a new technology for modifying human cells to create programmable therapeutics that could travel the body and selectively target cancer and other ...

Proper stem cell function requires hydrogen sulfide

9 hours ago

Stem cells in bone marrow need to produce hydrogen sulfide in order to properly multiply and form bone tissue, according to a new study from the Center for Craniofacial Molecular Biology at the Herman Ostrow School of Dentistry ...

User comments : 0

More news stories

Turning off depression in the brain

Scientists have traced vulnerability to depression-like behaviors in mice to out-of-balance electrical activity inside neurons of the brain's reward circuit and experimentally reversed it – but there's ...

Hackathon team's GoogolPlex gives Siri extra powers

( —Four freshmen at the University of Pennsylvania have taken Apple's personal assistant Siri to behave as a graduate-level executive assistant which, when asked, is capable of adjusting the temperature ...

Better thermal-imaging lens from waste sulfur

Sulfur left over from refining fossil fuels can be transformed into cheap, lightweight, plastic lenses for infrared devices, including night-vision goggles, a University of Arizona-led international team ...